World Pneumonia Day 2017, 12th of November
Read the latest research tackling pneumonia
Special article collection supports World Pneumonia Day
A child dies from pneumonia every 20 seconds; worldwide, the disease is responsible for almost one in six deaths in children under the age of five. World Pneumonia Day (12 November) was established to raise awareness and set forth a global action plan to prevent and treat the lung disease. To support the day, we have collated a special collection of some of the latest research published in Elsevier journals – free to access until 1st of February 2018.
In 2015, approximately 920,000 children died from pneumonia – that’s more than 2,500 children per day. Pneumonia is an infection in the lungs caused by bacteria, viruses or fungi. The disease can cause fluid build-up, lung damage, severe breathing issues and problems in other parts of the body.
Despite proven methods backed by the World Health Organization (WHO) and UNICEF in treating pneumonia with vaccines and other preventative methods, the majority of those affected live in communities who do not have easy access to medicines. Yet access to treatment does not guarantee avoidance or survival: in the US, 1 million adults are hospitalised with pneumonia every year, and 20 percent of them do not survive.
Research being done around the world helps tackle the disease and informs campaigns like World Pneumonia Day, by improving our knowledge, uncovering the most effective ways to stop pneumonia from spreading, and developing better treatments.
This special article collection features some of the latest research on pneumonia published in Elsevier journals. You can read about different pneumonia cases, treatments and the development of vaccines, by reading the collection – free until 1st of February 2018.
Clinical Microbiology and Infection
Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases
J.Rello, C. Solé-Lleonart, J.-J. Rouby, J. Chastre, S. Blot, G. Poulakou, C.-E. Luyt, J. Riera, L.B. Palmer, J.M. Pereira, T. Felton, J. Dhanani, M. Bassetti, T. Welte, J.A. Roberts
Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients
J. Rello, J.J. Rouby, C. Sole-Lleonart, J. Chastre, S. Blot, C.E. Luyt, J. Riera, M.C. Vos, A. Monsel, J. Dhanani, J.A. Roberts
Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis
C. Garcia-Vidal, I. Sanchez-Rodriguez, A.F. Simonetti, J. Burgos, D. Viasus, M.T. Martin, V. Falco, J. Carratalà
Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥ 60 years - a population-based retrospective cohort study
Martin Kolditz, Jochen Schmitt, Mathias W. Pletz, Falko Tesch
Journal of Infection
Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance
Laia Fernández-Barat, Miquel Ferrer, Francesca De Rosa, Albert Gabarrús, Mariano Esperatti, Silvia Terraneo, Mariano Rinaudo, Gianluigi Li Bassi, Antoni Torres
Pneumolysin as a potential therapeutic target in severe pneumococcal disease
Ronald Anderson, Charles Feldman
Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
Rosanel Amaro, Jacobo Sellarés, Eva Polverino, Catia Cillóniz, Miquel Ferrer, Laia Fernández-Barat, Josep Mensa, Michael S. Niederman, Antoni Torres
International Journal of Infectious Diseases
Community acquired infections among refugees leading to Intensive Care Unit admissions in Turkey
Mediha Turktan, Oznur Ak, Hakan Erdem, Dilek Ozcengiz, Sally Hargreaves, Safak Kaya, Emre Karakoc, Ozlem Ozkan-Kuscu, Gunay Tuncer-Ertem, Recep Tekin, Handan Birbicer, Gul Durmus, Canan Yilmaz, Funda Kocak, Edmond Puca, Jordi Rello
Respiratory viruses detected in Mexican children younger than 5 years old with community-acquired pneumonia: a national multicenter study
Rosa María Wong-Chew, Miguel L. García-León, Daniel E. Noyola, Luis F. Perez Gonzalez, Jesús Gaitan Meza, Alberto Vilaseñor-Sierra, Gerardo Martinez-Aguilar, Victor Hugo Rivera-Nuñez, Oscar A. Newton-Sánchez, Verónica Firo-Reyes, Carlos N. Del Río-Almendarez, Alejandra Pamela González-Rodríguez, Enrique R. Ortiz-García, Susana Navarrete-Navarro, Carmen Soria-Rodríguez, Adoniram Carrasco-Castillo, Eneida Sánchez-Medina, Irma López-Martínez, Teresa Hernández-Andrade, Celia M. Alpuche-Aranda, José I. Santos-Preciado, et al
High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea
H.S. Nam, J.W. Park, M. Ki, M.Y. Yeon, J. Kim, S.W. Kim
Journal of Global Antimicrobial Resistance
Diversity of blaOXA-51 variants and its clonal complexes in multidrug-resistant Acinetobacter baumannii strains in patients with ventilator-associated pneumonia
Mirna G. Moreira, Carlos H. Camargo, Francielli M. Vasconcellos, Lidia M. Barreto, Vandack Nobre, Simone G. Santos
Optimal duration of antimicrobial therapy in ventilator-associated pneumonia: What is the role for procalcitonin?
Marilia Rita Pinzone, Bruno Cacopardo, Lilian Abbo, Giuseppe Nunnari
Journal of Clinical Virology
Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe
Y. Alimi, W.S. Lim, L. Lansbury, J. Leonardi-Bee, J.S. Nguyen-Van-Tam
Frequency of respiratory viruses among patients admitted to 26 Intensive Care Units in seven consecutive winter-spring seasons (2009–2016) in Northern Italy
Antonio Piralla, Bianca Mariani, Francesca Rovida, Fausto Baldanti
An enhanced Enterovirus surveillance system allows identification and characterization of rare and emerging respiratory enteroviruses in Denmark, 2015–16
Céline Barnadas, Sofie E. Midgley, Marianne N. Skov, Lotte Jensen, Mille W. Poulsen, Thea Kølsen Fischer
International Journal of Antimicrobial Agents
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point
T.M. File Jr, P.B. Eckburg, G.H. Talbot, L. Llorens, H.D. Friedland
Journal of Infection and Chemotherapy
Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan
Akihiro Ito, Tadashi Ishida, Hironobu Tokumasu, Yasuyoshi Washio, Akio Yamazaki, YuheiItoa Hiromas, Tachibana
Australasian Emergency Nursing Journal
Accurate respiratory rates count: So should you!
Tracy Flenady, Trudy Dwyer, Judith Applegarth
Heart, Lung and Circulation
Right Heart Function During and After Community-Acquired Pneumonia in Adults
Kevin E.Boczar MD, Vicente F.Corrales-Medina MD, MSc, Ian G.Burwash MD, Julio A.Chirinos, PhD, Girish Dwivedi MD, PhD, DM, MRCP
Protective effects of tenuigenin on Staphylococcus aureus-induced pneumonia in mice
Bin Yu, Jiutao Qiao, Yongbin Shen, Lianyong Li